Prevention With Ismigen of RTIs in Kids (PIRTIK)
A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).
研究概览
详细说明
Respiratory tract infections (RTIs) are the leading cause of acute disease incidence worldwide that affect people of all ages. They are usually caused by viral pathogens, the most common of which including rhinoviruses, coronaviruses, adenoviruses, respiratory syncytial virus and influenza viruses. Bacterial pathogens can also cause RTIs, but they are less common. Various studies show the seasonality of RTIs. Influenza tends to occur in late autumn and winter, while other RTIs have a much more diffuse occurrence throughout the year. Although RTIs are usually not life-threatening, they significantly decrease quality of life and represent a substantial proportion of healthcare visits, mainly in women and young children, contributing to a financial burden on society.
Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) which is manufactured by mechanical lysis is currently authorized in two EU Member States (MS), Italy and Poland, where Lallemand Pharma Europe is the Marketing Authorization Holder (MAH) as sublingual tablets for the prophylaxis of recurrent RTI in adults. It is authorized in Poland in children from 3 years of age.
On 27 June 2019, the European Medicines Agency (EMA) recommended that bacterial lysates-containing medicinal products authorized for respiratory conditions should only be used for the prevention of recurrent respiratory tract infections, with the exception of pneumonia. This followed a review in which EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases. Although data are limited, the review found some evidence of effectiveness of bacterial lysates in the prevention of recurrent RTI together with a safety profile in line with what is expected for this type of product. The CHMP therefore recommended that use of bacterial lysates for prevention can continue, but the companies must provide further data on safety and effectiveness by Q1 2026 through the conduct of phase IV double-blind, multicenter, RCTs in this indication.
The present study is a Post-Authorization Efficacy Study (PAES) designed to demonstrate that PMBL® sublingual tablet used according to the SmPC instructions can reduce the incidence of respiratory tract infections in children 3 to 12 years old during the fall and winter period when compared to a matched Placebo.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Bernard GOUT, PharmD, PhD
- 电话号码:+33776583905
- 邮箱:bgout@pharmndev.ch
学习地点
-
-
-
Bialystok、波兰
- 招聘中
- Bio Zdrowie
-
Bydgoszcz、波兰
- 招聘中
- In Vivo Sp. z o.o.
-
Bydgoszcz、波兰
- 招聘中
- Vitamed
-
Krakow、波兰
- 招聘中
- Centrum Nowoczesnych Terapii
-
Krakow、波兰
- 尚未招聘
- Comarch Healthcare S.A.
-
Krakow、波兰
- 招聘中
- Linden Sp. z o.o. sp.k.
-
Lublin、波兰
- 招聘中
- Allergotest
-
Oświęcim、波兰
- 招聘中
- Medicome Sp. z o.o.
-
Poznan、波兰
- 招聘中
- Med - Polonia
-
Tarnów、波兰
- 招聘中
- Alergo-Med Specjalistyczna Przychodnia
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
描述
Inclusion Criteria:
- Children of both genders aged from 3 to 12 years.
- Written informed consent obtained from the parents/legally authorized representatives
- Written assent obtained from the subject from 7 years
- Subject presenting with a susceptibility to respiratory tract infections according to the investigator
- No respiratory tract infection within 15 days before the randomization visit
- All girls of childbearing potential have a negative pregnancy urine testing at randomization visit and are informed and their parents as well of the requirement for contraception during the study.
- A cooperative attitude and ability to correct use of PMBL® tablet.
Exclusion Criteria:
- Subject treated with bacterial lysates within the previous 6 months prior to V1 or ongoing treatment.
- Body temperature ≥ 37.5°C at the randomization visit.
- Pregnant/Lactating female or with sexual activity without hormonal contraception, intrauterine device or barrier methods.
- Primary or secondary immunodeficiency, cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, malignancy, endocrinological diseases or other chronic respiratory diseases, except asthma and allergic rhinitis.
- Known sensitivity to the components of study medication.
- Any major surgery within the last 3 months prior to study enrolment or planned to occur within the duration of study.
Treatment with the following medications:
- Injection or oral administration of steroids within 4 weeks prior to study enrolment.
- Previous and/or concomitant immunosuppressants, immunostimulants, allergen-immunotherapy or gamma globulins within 6 months prior to study enrolment.
- Inability to understand or comply with study procedures or with study treatment intake.
- Subject participating in another interventional clinical study at the time of screening visit.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:PMBL® sublingual tablet
Ismigen® (Polyvalent Mechanical Bacterial Lysate; PMBL) is a sublingual tablet marketed by Lallemand Pharma Europe. Each tablet contains:
The posology of Ismigen® for paediatric population (from 3 years of age) is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months. |
3-month period, 10 days per months during the fall-winter
其他名称:
|
|
安慰剂比较:Placebo
The comparator is a sublingual tablet, indistinguishable from the investigational product. Each tablet of placebo comparator has the same composition as the investigational medicinal product being tested (with the exception of the active substance, which is replaced by glycine (7 mg)). Posology, instructions for use, contraindications, precautions of use and labelling are identical to those for Ismigen®. The posology of Placebo is one tablet per day before food, to be dissolved under the tongue. Use for ten consecutive days per month, over a period of 3 months. |
3-month period, 10 days per months during the fall-winter
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The total number of RTIs experienced by each subject throughout the 7-month study period (3-month treatment + 4-month follow-up).
大体时间:Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Rate of Respiratory Tract Infections (RTIs): the number of RTIs experienced by a subject throughout the study (3 month-treatment period and 4 month-follow-up) will be assessed.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean duration in days per RTI during the overall study period.
大体时间:Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Estimated treatment effect from MMRM with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Number of days with respiratory tract infections during the overall study period
大体时间:Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Negative binomial or Poisson regression with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Number of days of antibiotics use during the overall study period
大体时间:Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
Estimated incidence rate ratio (IRR) using negative binomial regression (or Poisson if appropriate) with 95% CI.
|
Throughout the 7-month study period (3-month treatment + 4-month follow-up).
|
|
Total number of workdays lost by parents due to their child's respiratory infections during the overall study period.
大体时间:Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Total number of workdays lost by children's parents due to the child's respiratory infections during the overall study period (cumulative days) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of physician consultations due to RTI or related complications.
大体时间:Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Number of physician consultations due to RTI or related complications during the overall study period (count) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of antibiotic treatments (courses) for a respiratory event during the overall study period.
大体时间:Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Number of antibiotic treatments courses for a respiratory event during the overall study period (count of courses) For each endpoint: mean (SD), median (IQR), and cumulative counts by treatment arm; primary between-group effect presented as an incidence rate ratio (IRR) with 95% CI (PMBL® vs placebo).
Absolute mean difference and 95% CI will also be provided for interpretability
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
|
Number of subjects with (serious) adverse event and (serious) adverse drug reaction
大体时间:Throughout the study (3 month-treatment period and 4 month-follow-up)
|
Descriptive statistics: number and proportion of subjects experiencing events by type and severity Number and type of AEs, SAEs, and SARs during the study period
|
Throughout the study (3 month-treatment period and 4 month-follow-up)
|
合作者和调查者
调查人员
- 首席研究员:Andrzej EMERYK, MD, PhD、University Children Hospital, Lublin, Poland
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- LPI-2501
- 2025-524212-11-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.